Abstract
Netilmicin was used to treat 25 patients with serious Gram-negative bacillary infections. Initial dosage was 2·5 mg/kg in most patients and average daily dosage 4·4 mg/kg. Thirteen patients had urinary tract infections, 6 pleuropulmonary infections, and 7 miscellaneous infections. Eight patients were also bacteraemic. Nine infections were due to pathogens resistant to gentamicin in vitro; 6 had failed to resolve during gentamicin therapy. Twenty-one patients responded favourably (cure or improvement). Six patients developed partially reversible renal insufficiency, one reversible tinnitus, another transient eosinophilia and 4 mild reversible liver enzyme elevations. Mean blood levels were 7·4 μg/ml (peak) and 2·8 μg/ml (trough). Netilmicin is an effective antibiotic with potential use in hospitals with a high prevalence of gentamicin-resistant organisms.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call